Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.
Type:
Grant
Filed:
July 17, 2017
Date of Patent:
September 4, 2018
Assignee:
Allergan, Inc.
Inventors:
James Chang, Patrick Hughes, Chin-Ming Chang
Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
September 4, 2018
Assignee:
Allergan, Inc.
Inventors:
Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
Abstract: Provided herein are multiple solid forms of a defined steroid-like compound, and methods for the preparation and use thereof. In one aspect, there is provided a crystalline form of said steroid-like compound, and methods for the preparation and use thereof. In another aspect, there is provided a substantially amorphous form of said steroid-like compound, and methods for the preparation and use thereof. In yet another aspect, there are provided compositions containing compounds according to the present invention. In certain aspects, such compositions are suitable for delivery of active agents according to the present invention to a subject in need thereof. In another aspect of the invention, there are provided methods for the treatment of a variety of indications, including glaucoma, ocular hypertension, and the like. In still another aspect of the present invention, there are provided kits containing compounds according to the present invention and/or compositions containing same.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
September 4, 2018
Assignee:
ALLERGAN, INC.
Inventors:
Shaoxin Feng, Scott W. Smith, Olivier M. G. Lambert, Suzanne M. Buttar
Abstract: The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intraocular pressure and treatment of glaucoma.
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
August 28, 2018
Assignee:
ALLERGAN, INC.
Inventors:
Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly, Jie Shen, Marina Bejanian, Rhett Schiffman
Abstract: A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.
Abstract: A laminate useful as a component of a medical implant, for example, useful as a component of an inflatable tissue expander. The laminate includes a base layer, an intermediate layer, and a top layer. When used as a component of a tissue expander, the laminate enables an internal chamber pressure of about 2.5 psi with an expander exterior compressive force of about 40 lbs.
Type:
Grant
Filed:
November 24, 2015
Date of Patent:
August 21, 2018
Assignee:
Allergan, Inc.
Inventors:
Kaustubh S. Chitre, Nicholas Manesis, Nikhil S. Trilokekar, Dustin Leslie, David J. Schuessler
Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
Type:
Grant
Filed:
September 28, 2016
Date of Patent:
August 14, 2018
Assignee:
ALLERGAN, INC.
Inventors:
June Chen, David F. Woodward, Alexander B. Kharlamb
Abstract: Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. The assisted syringes can be used to inject or extrude viscous materials.
Type:
Grant
Filed:
May 1, 2015
Date of Patent:
July 24, 2018
Assignee:
Allergan, Inc.
Inventors:
Jason S. Metzner, Zachary Dominguez, Justin J. Schwab, Ethan Franklin, Mike Augarten
Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
July 3, 2018
Assignee:
ALLERGAN, INC.
Inventors:
Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
Type:
Grant
Filed:
November 14, 2016
Date of Patent:
May 29, 2018
Assignee:
Allergan, Inc.
Inventors:
Alazar N. Ghebremeskel, Michael R. Robinson
Abstract: Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same.
Type:
Grant
Filed:
May 12, 2015
Date of Patent:
May 29, 2018
Assignee:
ALLERGAN, INC.
Inventors:
Robert M. Burk, David W. Old, Wha Bin Im, Richard S. Graham, Mu-Lan Lee
Abstract: A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.
Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
May 22, 2018
Assignee:
Allergan, Inc.
Inventors:
Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
Type:
Grant
Filed:
January 18, 2017
Date of Patent:
May 22, 2018
Assignee:
Allergan, Inc.
Inventors:
Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
Type:
Grant
Filed:
June 9, 2016
Date of Patent:
May 8, 2018
Assignee:
Allergan, Inc.
Inventors:
Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang, Athene Wan Chie Chan
Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
April 24, 2018
Assignee:
Allergan, Inc.
Inventors:
Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Sumit Paliwal, Nicholas J. Manesis